Hologic, Inc.

Equities

HOLX

US4364401012

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-05 EDT			5-day change	1st Jan Change
74.12 ^USD	+0.87%		-0.18%	+3.74%

07-02	Evercore ISI Adjusts Price Target on Hologic to $76 From $78, Maintains In-line Rating	MT
06-27	Stephens Initiates Coverage on Hologic With Overweight Rating, $87 Price Target	MT

Hologic, Inc. Reports Earnings Results for the First Quarter Ended December 26, 2020

January 27, 2021 at 04:11 pm

Hologic, Inc. announced earnings results for the first quarter ended December 26, 2020. For the first quarter, the company announced total revenue was USD 1,609.8 million compared to USD 850.5 million a year ago. Operating income was USD 885.5 million compared to USD 124.8 million a year ago. Net income was USD 654.4 million compared to USD 386.1 million a year ago. Basic earnings per share from continuing operations was USD 2.53 compared to USD 1.44 a year ago. Diluted earnings per share from continuing operations was USD 2.5 compared to USD 1.43 a year ago.

Latest news about Hologic, Inc.

Evercore ISI Adjusts Price Target on Hologic to $76 From $78, Maintains In-line Rating	07-02	MT
Stephens Initiates Coverage on Hologic With Overweight Rating, $87 Price Target	06-27	MT
Lumos Diagnostics Receives $400,000 in Milestone Payment from Hologic; Shares Up 3%	06-19	MT
Transcript : Hologic, Inc. Presents at The 44th Annual William Blair Growth Stock Conference, Jun-04-2024 08:40 AM	06-04
Transcript : Hologic, Inc. Presents at 2024 Leerink Partners Healthcare Crossroads Conference, May-29-2024 10:00 AM	05-29
FDA classifies recall of Hologic's implant as 'most serious'	05-22	RE
FDA classifies recall of Hologic's implants for soft tissue as 'most serious'	05-22	RE
Argus Adjusts Price Target on Hologic to $95 From $89	05-09	MT
Lumos Diagnostics Concludes Initial Phase of Development Deal with Hologic for Fetal Fibronectin Test; Shares Jump 6%	05-05	MT
JPMorgan Adjusts Price Target on Hologic to $91 From $85	05-03	MT
UBS Adjusts Price Target on Hologic to $81 From $79, Maintains Neutral Rating	05-03	MT
Tranche Update on Hologic, Inc.'s Equity Buyback Plan announced on September 23, 2022.	05-03	CI
Hologic Fiscal Q2 Earnings, Revenue Decline; Q3 Outlook Issued, Fiscal 2024 Estimates Revised -- Shares Up After Hours	05-02	MT
Transcript : Hologic, Inc., Q2 2024 Earnings Call, May 02, 2024	05-02
Earnings Flash (HOLX) HOLOGIC Posts Q2 EPS $1.03, vs. Street Est of $0.98	05-02	MT
Earnings Flash (HOLX) HOLOGIC Reports Q2 Revenue $1.02B, vs. Street Est of $1B	05-02	MT
(HOLX) HOLOGIC Expects Fiscal Year 2024 EPS Range $4.02 - $4.12	05-02	MT
(HOLX) HOLOGIC Sees Q3 EPS Range $0.98 - $1.05	05-02	MT
Hologic, Inc. Reports Impairment of Intangible Assets for the Second Quarter Ended March 30, 2024	05-02	CI
Hologic, Inc. Revises Earnings Guidance for the Fiscal Year 2024	05-02	CI
Hologic, Inc. Provides Earnings Guidance for the Third Quarter of Fiscal 2024	05-02	CI
Hologic, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 30, 2024	05-02	CI
Molten Ventures portfolio firm gets bought by Hologic	04-30	AN
Molten Ventures portfolio firm to buy Endomagnetics for USD310 million	04-30	AN
Hologic to Acquire Breast Cancer Surgery Technology Firm Endomagnetics For $310 Million	04-29	MT

Chart Hologic, Inc.

Duration

Period

More charts

Company Profile

Hologic, Inc. is the world leader in the design, manufacturing and marketing of diagnostic products, medical imaging systems and surgical products dedicated to women's health. Net sales break down by area of application as follows: - molecular diagnostics (46.7%): rapid diagnostic tests for human diseases detection (sexually transmitted infections, respiratory diseases, viral diseases, infectious diseases, cancers of the cervix and prostate, etc.) and fetal fibronectin; - breast health (35.5%): digital mammography and breast biopsy solutions and systems; - gynecological surgery (15%): endometrial ablation devices, minimally invasive intervention systems for the hysteroscopic elimination of targeted intrauterine diseases (including fibroids and polyps). The group also offers fluid management systems for use in hysteroscopic procedures; - bone health (2.8%): bone imaging systems, bone sonometers and osteodensitometers for bone structure and density, and osteoporotic fractures risk assessment. Net sales break down by source of revenue between sales of products (81.4%) and services (18.6%). Net sales are distributed geographically as follows: the United States (75.9%), Europe (12.9%), Asia/Pacific (6.3%) and other (4.9%).

Sector

Advanced Medical Equipment & Technology

Calendar

2024-07-29 - Q3 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Hologic, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

74.1 USD

Average target price

85.13 USD

Spread / Average Target

+14.89%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HOLOGIC, INC.	+3.74%	17.29B
THERMO FISHER SCIENTIFIC	+1.75%	206B
DANAHER CORPORATION	+3.42%	177B
INTUITIVE SURGICAL, INC.	+31.54%	157B
BOSTON SCIENTIFIC CORPORATION	+32.16%	112B
EDWARDS LIFESCIENCES CORPORATION	+21.08%	55.63B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-1.61%	47.57B
AGILENT TECHNOLOGIES, INC.	-9.11%	36.87B
GE HEALTHCARE TECHNOLOGIES INC.	-0.34%	35.18B
RESMED, INC.	+13.21%	28.61B

Other Advanced Medical Equipment & Technology